Business Summary
Immunome, Inc. is a clinical-stage biotechnology company focused on developing first-in-class and best-in-class targeted oncology therapies, with deep expertise in antibody-drug conjugates (ADCs) and other oncology modalities. The company's lead asset, varegacestat (formerly AL102, acquired from Ayala Pharmaceuticals in March 2024), is an oral gamma secretase inhibitor that achieved highly significant Phase 3 results in December 2025 for desmoid tumors, with an NDA submission planned for Q2 2026. Immunome has no approved products and no product revenue to date, carrying an accumulated deficit of $728.2 million as of December 31, 2025.
Products & Services
Clinical Stage: - Varegacestat — oral, once-daily gamma secretase inhibitor (GSI) for desmoid tumors; Phase 3 RINGSIDE trial met all primary and key secondary endpoints (84% reduction in progression risk vs. placebo, HR=0.16; ORR 56% vs. 9%); NDA submission targeted Q2 2026 - IM-1021 — ROR1-targeting ADC utilizing proprietary HC74 TOP1 inhibitor...
AI-generated summary of Item 1 (Business) from the 10-K filed Mar 3, 2026 — View filing on SEC.gov. May contain errors — refer to the filing for authoritative information.
Across SEC filings
Institutional holders · 13F
Q3 2026| Largest holders | Reported value |
|---|---|
| T Rowe Price Investment Management Inc | $434.7M |
| FMR LLC | $366.5M |
| BlackRock Inc | $192.1M |
| WELLINGTON MANAGEMENT GROUP LLP | $129.9M |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $107.1M |
Annual results · 10-K
Fiscal 2025- Revenue
- $6.9M
- Net loss
- -$212.4M
As reported in the fiscal 2025 annual report.
Funds & ETFs · N-PORT
218 funds| Fund | Value | % of fund |
|---|---|---|
| T. Rowe Price Small-Cap Stock Fund, Inc. | $152.1M | 1.64% |
| Fidelity Growth Company Fund | $134.4M | 0.14% |
| VANGUARD HEALTH CARE FUND | $84.3M | 0.22% |
| PRIMECAP Odyssey Aggressive Growth Fund | $84.1M | 1.14% |
| T. Rowe Price Institutional Small-Cap Stock Fund | $82.8M | 1.65% |
| VANGUARD TOTAL STOCK MARKET INDEX FUND VTI | $68.3M | < 0.01% |
| State Street(R) SPDR(R) S&P(R) Biotech ETF XBI | $63.4M | 0.59% |
| Select Biotechnology Portfolio | $58.4M | 0.93% |
| iShares Russell 2000 ETF IWM | $58.2M | 0.07% |
| Fidelity Growth Company K6 Fund | $38.8M | 0.14% |
218 funds reported holding $1.3B in total on their latest public Form N-PORT reports, the most recent dated September 2026. Security record
Insider trades · Form 4
Latest filings
- Jack Higgins 2026-09-15 Sell
- Isaac Barchas 2026-08-12 Sell
- Isaac Barchas 2026-08-10 Sell
- Kinney Horn 2026-08-06 Sell
- Kinney Horn 2026-07-27 Award
5%+ holders · 13D/G
7 filers| Filer | % of class | Filed |
|---|---|---|
| WELLINGTON MANAGEMENT GROUP LLP 13G | 5.3% | 2026-11-16 |
| VANGUARD CAPITAL MANAGEMENT LLC 13G | 5.0% | 2026-10-30 |
| T Rowe Price Investment Management Inc 13G | 17.4% | 2026-08-14 |
| Enavate Sciences GP LLC 13D | 4.3% | 2025-12-22 |
| FMR LLC 13G | 15.0% | 2025-10-07 |
| JANUS HENDERSON GROUP PLC 13G | 2.2% | 2025-05-14 |
| Immunome Aggregator LP 13D | 6.0% | 2025-02-04 |
Latest Schedule 13D or 13G from each filer; stakes a filer has reported closed are left out.
Federal lobbying · LD-2
Securities
| CUSIP | Security | Type |
|---|---|---|
| 45257U108 | IMNM IMMUNOME INC | Common stock |